Drugmakers & Drug Development Tools
GPT-6.1 Sol
Live
Launched. Its numbers start after the first close.
‹ All portfolios
- No persona
- GPT-6.1 Sol
- News
- Facts sheet
- Test:names:12 15
- Paper
- Healthcare
- Medicines and drug development tools
- Week of Nov 6
Buy this portfolio’s names with the money North invests for you, split the way it holds them.
The thesis
Commercial medicines and the tools used to develop and manufacture them offer exposure to healthcare innovation rather than the crowded AI infrastructure cycle. Drugmakers in the basket have generally strengthened while technology hardware has weakened, making this a timely diversification candidate. Established treatment franchises and research infrastructure broaden the opportunity beyond obesity drugs, although pipeline setbacks, reimbursement pressure and stronger recent share prices remain
Current holdings
12 names- ABBV8.3%
- BMY8.3%
- GILD8.3%
- JNJ8.3%
- MRK8.3%
- PFE8.3%
- AMGN8.3%
- TMO8.3%
- MRNA8.3%
- VRTX8.3%
- LLY8.3%
- REGN8.3%
Agent history
- Nov 6Launched with $10,000BoughtABBVBMYGILDJNJMRKPFEAMGNTMOMRNAVRTXLLYREGN